ResearchAndMarkets.com added separate market reports on Duchenne muscular dystrophy (DMD) and Von Willebrand disease (VWD) across the seven major markets (7MM)—the United States, Germany, France, Italy, Spain, the United Kingdom and Japan—with forecasts through 2036. The DMD market reached approximately USD 4.00 billion in 2025 and is projected to grow at an 11% compound annual growth rate from 2026 to 2036, while the VWD market is expected to expand as diagnosis, treatment access and routine prophylaxis improve. The DMD report estimates approximately 32,000 prevalent cases across the 7MM in 2025, including about 17,500 in the United States, and identifies VILTEPSO, which generated approximately USD 560 million in 2025, as the leading therapy by revenue. The VWD report says diagnosed prevalence will rise through 2036; in the United States, females represented approximately 55% of diagnosed cases and Type 1 accounted for about 83%. The reports examine treatment practices, therapy uptake, market size, pricing, reimbursement, regulatory developments, competitive dynamics and unmet needs. DMD growth is linked to gene therapy, exon skipping, earlier genetic diagnosis and candidates including pizuglanstat and RGX-202; VWD opportunities center on established products WILATE and VONVENDI/VEYVONDI and investigational therapies VGA039, HMB-002 and ALN-6400.